Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non‑Hodgkin's lymphoma: 
A prospective study of 46 cases

Wu,Hongyang; Zhao,Chenchen; Gu,Kangsheng; Jiao,Yang; Hao,Jiqing; Sun,Guoping

doi:10.3892/mco.2014.307

Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non‑Hodgkin's lymphoma: A prospective study of 46 cases

Authors:
- Hongyang Wu
- Chenchen Zhao
- Kangsheng Gu
- Yang Jiao
- Jiqing Hao
- Guoping Sun
View Affiliations

Affiliations: Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230031, P.R. China
Published online on: June 6, 2014 https://doi.org/10.3892/mco.2014.307
Pages: 695-700

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The treatment of T-cell non-Hodgkin's lymphoma (T‑NHL) remains challenging. There is currently no standard regimen for the treatment of T-NHL in the first‑ or second‑line setting. thalidomide was previously shown to exert antitumor effects through inhibiting angiogenesis, promoting apoptosis and immunomodulatory activity. However, all the previous studies on the treatment of lymphoma with thalidomide included patient samples of limited size. In the present study, 46 cases of eligible T-NHL patients were randomized into i) the control group (conventional combined chemotherapy, n=22) and ii) the thalidomide group (thalidomide plus combined chemotherapy, n=24). the median dose of thalidomide was 200 mg (range, 150‑400 mg) every night, without reported severe side effects. The clinical response to treatment was as follows: Complete response (CR) in 12 cases, partial response (PR) in 7, stable disease (SD) in 1 and progressive disease (PD) in 4 cases in the thalidomide group; and CR in 8 cases, PR in 6, SD in 3 and PD in 5 cases in the control group. The CR rate was 50.0 and 36.4% in the thalidomide and the control groups, respectively (P<0.05). The median progression‑free and overall survival were 12 and undefined months, respectively, in the thalidomide group and 6 and 17 months, respectively, in the control group. The toxicity profile was considered acceptable in both groups. Our results indicated that thalidomide plus combined chemotherapy may exhibit enhanced efficacy in the clinical treatment of T-NHL. In addition, this type of treatment may reduce the frequency of adverse gastrointestinal reactions and help alleviate fear of chemotherapy. Therefore, thalidomide plus combined chemotherapy may be a viable option for the clinical treatment of T-NHL.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Ekström-Smedby K: Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncol. 45:258–271. 2006.
3	Vose J, Armitage J and Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
4	Shiels MS, Engels EA, Linet MS, et al: The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992–2009. Cancer Epidemiol Biomarkers Prev. 22:1069–1078. 2013.PubMed/NCBI
5	Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood. 92:76–82. 1998.
6	Reimer P, Rüdiger T, Geissinger E, et al: Autologous stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 27:106–113. 2009. View Article : Google Scholar : PubMed/NCBI
7	Jagadeesh D and Smith MR: Novel targeted therapies in peripheral T cell lymphoma. Discov Med. 15:367–378. 2013.PubMed/NCBI
8	Somers GF: Pharmacological properties of thalidomide (alpha-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol Chemother. 15:111–116. 1960. View Article : Google Scholar : PubMed/NCBI
9	Tseng S, Pak G, Washenik K, Pomeranz MK and Shupack JL: Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 35:969–979. 1996. View Article : Google Scholar : PubMed/NCBI
10	Kruse FE, Joussen AM, Rohrschneider K, Becker MD and Völcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 236:461–466. 1998. View Article : Google Scholar : PubMed/NCBI
11	Aseffa A, Dietrich MA and Shannon EJ: Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Immunopharmacol Immunotoxicol. 19:313–326. 1997. View Article : Google Scholar : PubMed/NCBI
12	Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
13	FDA. FDA Approves Thalomid (thalidomide) to Treat Multiple Myeloma. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107296.htm. Accessed May 18, 2014
14	Krown SE: Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol. 13:374–381. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kaufmann H, Raderer M, Wöhrer S, et al: Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood. 104:2269–2271. 2004. View Article : Google Scholar : PubMed/NCBI
16	Strupp C, Germing U, Scherer A, et al: Thalidomide for the treatment of idiopathic myelofibrosis. Eur J Haematol. 72:52–57. 2004. View Article : Google Scholar : PubMed/NCBI
17	Ramírez J, Wu K, Janisch L, et al: The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. Cancer Chemother Pharmacol. 68:1629–1632. 2011.PubMed/NCBI
18	Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. International Agency for Research on Cancer Press; Lyon: 2008
19	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
20	Huang HQ, Peng YL, Lin XB, et al: Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen. Chin J Cancer. 23(Suppl 11): S1443–S1447. 2004.(In Chinese).
21	Haas PS, Denz U, Ihorst G and Engelhardt M: Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol. 80:303–309. 2008. View Article : Google Scholar
22	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
23	NCI. Cancer therapy evaluation program, common terminology criteria for adverse events. Version 3.0. Dec 12–2003, Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed May 18, 2014
24	Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 114:237–267. 2012. View Article : Google Scholar : PubMed/NCBI
25	Govindarajan R: Irinotecan/thalidomide in metastatic colorectal cancer. Oncology (Williston Park). 16(Suppl 3): S23–S26. 2002.
26	Majumder S, Sreedhara SR, Banerjee S and Chatterjee S: TNF α signaling beholds thalidomide saga: a review of mechanistic role of TNF-α signaling under thalidomide. Curr Top Med Chem. 12:1456–1467. 2012.
27	Ladizinski B, Shannon EJ, Sanchez MR and Levis WR: Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. J Drugs Dermatol. 9:814–826. 2010.PubMed/NCBI
28	Mei SC and Wu RT: The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. Mol Cancer Ther. 7:2405–2414. 2008. View Article : Google Scholar : PubMed/NCBI
29	Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R and Binion DG: Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol. 298:G167–G176. 2010. View Article : Google Scholar : PubMed/NCBI
30	Lin YC, Shun CT, Wu MS and Chen CC: A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res. 12:7165–7173. 2006. View Article : Google Scholar
31	Zhu YX, Kortuem KM and Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 54:683–687. 2013. View Article : Google Scholar : PubMed/NCBI
32	Strupp C, Aivado M, Germing U, Gattermann N and Haas R: Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma. 43:133–137. 2002. View Article : Google Scholar : PubMed/NCBI
33	Wilson EA, Jobanputra S, Jackson R, Parker AN and McQuaker IG: Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br J Haematol. 119:128–130. 2002. View Article : Google Scholar : PubMed/NCBI
34	Damaj G, Lefrère F, Delarue R, Varet B, Furman R and Hermine O: Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 17:1914–1915. 2003. View Article : Google Scholar : PubMed/NCBI
35	Pro B, Younes A, Albitar M, et al: Thalidomide for patients with recurrent lymphoma. Cancer. 100:1186–1189. 2004. View Article : Google Scholar : PubMed/NCBI
36	Su X, Zhang R, Liu H, et al: Clinical study of E-CHOP plus thalidomide in treatment of advanced non-Hodgkin’s lymphoma. China Pharmaceuticals. 17:53–55. 2008.
37	Damaj G, Bouabdallah R, Vey N, Bilger K, Mohty M and Gastaut JA: Single-agent thalidomide induces response in T-cell lymphoma. Eur J Haematol. 74:169–171. 2005. View Article : Google Scholar : PubMed/NCBI
38	Dogan A, Ngu LS, Ng SH and Cervi PL: Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia. 19:873–875. 2005. View Article : Google Scholar : PubMed/NCBI
39	Tassinari D, Santelmo C, Tombesi P and Sartori S: Thalidomide in the treatment of cancer cachexia. J Palliat Care. 24:187–189. 2008.PubMed/NCBI
40	Carrier M, Le Gal G, Tay J, Wu C and Lee AY: Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost. 9:653–663. 2011. View Article : Google Scholar
41	Zhu D, Corral LG, Fleming YW and Stein B: Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother. 57:1849–1859. 2008. View Article : Google Scholar : PubMed/NCBI